Bevacizumab in the therapy for refractory metastatic colorectal cancer
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the u...
Guardado en:
Autor principal: | Mary F Mulcahy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c87ea3c9c05e47798ea5dcaa53730154 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Yeong Hak Bang, et al.
Publicado: (2021) -
Ziv-aflibercept in metastatic colorectal cancer
por: Patel A, et al.
Publicado: (2013) -
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Shannon Puhalla, et al.
Publicado: (2008) -
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo M, et al.
Publicado: (2015) -
Bevacizumab in the treatment of ovarian cancer
por: Ramez N Eskander, et al.
Publicado: (2011)